A May whistleblower complaint alleged that the FDA’s emergency authorization of chloroquine and hydroxychloroquine came about as a result of political pressure from the White House.
because of numerous problems, including failing to include the outcomes of patients on the drugs who died or were hospitalized. The review also cited a small Chinese trial of 30 patients that showed the drugs had little to no effect on patient outcomes, and a letter from Chinese scientists that said it was effective – but was not backed up with any data.
The document also reviewed the risks posed by the millions of doses of the drugs that were donated for use in the US. Analyzing the 1 million chloroquine tablets donated to the US by Bayer Pharmaceuticals, the review noted they were made at never-inspected factories in India with “a low reputation for quality.” The pills were made by a manufacturer in India whose other factories had failed previous FDA inspections.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Russians claim to have an effective treatment for the coronavirus, which hospitals will start using in JuneRussia has approved an anti-influenza drug to treat Covid-19 and will start delivering courses of the drug, Avifavir, to hospitals in June, according to Russia's sovereign wealth fund (RDIF).
続きを読む »
South Korea's Celltrion says COVID-19 drug shows drop in viral load in animal testingSouth Korea's Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated a 100-fold reduction in viral load of the disease in animal testing.
続きを読む »
Gilead says remdesivir helped moderate COVID-19 patients improveGilead Sciences Inc said on Monday its antiviral drug remdesivir showed improvement in patients with moderate COVID-19 in a late-stage study.
続きを読む »
Gilead trades that made millions on COVID-19 drug news raise eyebrowsWell-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
続きを読む »
Exclusive: Russia, after approving Japanese COVID-19 drug, to roll out 'game changer' next weekRussia will start administering its first approved antiviral drug to treat coronavirus patients next week, its state financial backer told Reuters, a move it described as 'a game changer' that should speed a return to normal economic life.
続きを読む »
South Korea's Celltrion aims to start in-human COVID-19 drug trial in JulySouth Korea's Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated an up to 100-fold reduction in viral load of the disease in animal testing, saying it aims to start in-human clinical trials in late July.
続きを読む »